• Explore /
  • Poster
  • / Prognostic and predictive factors in patients treated with ramucirumab (RAM) with advanced hepatocellular carcinoma (aHCC) and elevated alpha-fetoprotein (AFP): Results from two phase III trials.

Prognostic and predictive factors in patients treated with ramucirumab (RAM) with advanced hepatocellular carcinoma (aHCC) and elevated alpha-fetoprotein (AFP): Results from two phase III trials.

Abstract Poster

Authors

null

Josep M. Llovet

Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

Josep M. Llovet , Amit G. Singal , Augusto Villanueva , Richard S. Finn , Masatoshi Kudo , Peter R. Galle , Chunxiao Wang , Ryan C Widau , Elena Gonzalez Gugel , Andrew X. Zhu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Other GI Cancer

Clinical Trial Registration Number

NCT01140347; NCT02435433

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 4146)

DOI

10.1200/JCO.2021.39.15_suppl.4146

Abstract #

4146

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Andrew X. Zhu

First Author: Masatoshi Kudo

First Author: Peter R. Galle

First Author: Maria Reig